Opendata, web and dolomites

PersonalizeAF SIGNED

Personalized Therapies for Atrial Fibrillation. A Translational Approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PersonalizeAF project word cloud

Explore the words cloud of the PersonalizeAF project. It provides you a very rough idea of what is the project "PersonalizeAF" about.

skilled    staff    cardiology    mechanisms    care    guarantee    aggregates    medical    billion    patient    arrhythmia    health    partnership    clinical    profile    services    combining    career    treatments    biomedical    individualized    disseminate    point    innovative    multinational    stakeholders    characterization    models    individually    technologies    evaluation    generate    careers    specialised    create    treatment    training    public    ex    effect    data    cardiac    efficient    search    fibrillation    description    personalizeaf    af    outstanding    muscle    encourage    budget       integrate    train    date    academic    exceeding    atrial    human    esrs    world    engineering    commensurate    generation    vivo    students    therapies    substrate    million    europeans    13    personalised    therapy    view    multidisciplinary    companies    animal    annually    young    spectrum    delivering    phd    substrates    equivalent    silico    individual    strategies    sectors    efficiency    professionals    progress    disease    vitro    scientific    sectorial    vocational    purpose   

Project "PersonalizeAF" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT POLITECNICA DE VALENCIA 

Organization address
address: CAMINO DE VERA SN EDIFICIO 3A
city: VALENCIA
postcode: 46022
website: www.upv.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙943˙449 €
 EC max contribution 3˙943˙449 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2024-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT POLITECNICA DE VALENCIA ES (VALENCIA) coordinator 501˙809.00
2    KARLSRUHER INSTITUT FUER TECHNOLOGIE DE (KARLSRUHE) participant 758˙365.00
3    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 531˙239.00
4    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 303˙172.00
5    SIMULA RESEARCH LABORATORY AS NO (FORNEBU) participant 292˙342.00
6    UNIVERSITE DE BORDEAUX FR (BORDEAUX) participant 274˙802.00
7    NCARDIA BV NL (LEIDEN) participant 265˙619.00
8    ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA IT (BOLOGNA) participant 261˙499.00
9    UNIVERSITAETSKLINIKUM FREIBURG DE (FREIBURG) participant 252˙788.00
10    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 250˙904.00
11    FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANON ES (MADRID) participant 250˙904.00

Map

 Project objective

Atrial Fibrillation (AF) is the most common cardiac arrhythmia affecting more than 6 million Europeans with a cost exceeding 1% of the EU health care system budget (13.5 billion annually). New treatment strategies and the progress achieved in research on AF mechanisms and substrate evaluation methods to date have not been commensurate with an equivalent development of the knowledge and technologies required to individually characterize each patient in search of the most efficient therapy.

PersonalizeAF addresses this challenge by delivering an innovative multinational, multi-sectorial, and multidisciplinary research and training programme in new technologies and novel strategies for individualized characterization of AF substrate to and increase treatments’ efficiency.

From the research point of view, PersonalizeAF will integrate data and knowledge from in-vitro, in silico, ex vivo and in vivo animal and human models to: 1) generate an individual description of the state of the atrial muscle identifying the disease mechanisms and characteristics; 2) understanding the potential effect that different therapies have on different atrial substrates; and 3) combining this information to generate a specific profile of the patient and the best therapy for each patient.

With this purpose, PersonalizeAF partnership aggregates relevant scientific staff from the academic and clinical world with highly specialised biomedical companies which will be involved in a high-level personalised training programme that will train a new generation of highly skilled professionals and guarantee ESRs and future PhD students outstanding Career Opportunities in the biomedical engineering, cardiology services and medical devices sectors. PersonalizeAF will disseminate results to a wide spectrum of stakeholders, create awareness in the general public about atrial fibrillation and encourage vocational careers among young students.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERSONALIZEAF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PERSONALIZEAF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More  

WON (2019)

Wideband Optical Networks

Read More